Medical isotope firm Shine Medical Technologies soon may have two new investors from Indonesia.
The company has signed a three-way memorandum of understanding with PT Industri Nuklir Indonesia and IPTN North America to invest in Shine's planned molybdenum-99 (Mo-99) production facility in Janesville, WI. Mo-99 decays into technetium-99m, the most commonly used radioisotope in nuclear medicine.
The trio is also considering the possibility of building a second facility in Indonesia to serve the Eastern Hemisphere.